Category - Developments

Developments

Telix in PSMA collaboration with Profound Medical and other prostate cancer therapy players

Telix Pharmaceuticals (ASX:TLX, NASDAQ:TLX) announced that it has entered into letters of intent to pursue collaborations to explore the investigational use of its PSMA-PET imaging agents Gozellix (kit for the...

May 15, 2026

Developments

BriaCell expands pipeline to ovarian cancer candidate

BriaCell Therapeutics (NASDAQ: BCTX, BCTXL; TSX: BCT) has announced progress in developing Bria-OVA+, its next generation, personalized, off-the-shelf, cell-based immunotherapy for ovarian cancer. According to the...

May 15, 2026

Developments

Rigel enters into licensing agreement with Arvinas and Pfizer

Rigel Pharmaceuticals (NASDAQ: RIGL) has announced that it has entered into an exclusive, global license agreement with Arvinas (NASDAQ: ARVN) and Pfizer (NYSE: PFE), subject to regulatory clearance, to develop...

May 12, 2026

Developments

MindMaze and Vibra ink partnership to scale neurotherapeutics across U.S.

MindMaze Therapeutics (SIX: MMTX) has announced the signing of a definitive channel partnership agreement with closely held Vibra Healthcare to introduce MindMaze’s FDA-cleared digital neurotherapeutics platform to U.S...

May 12, 2026

Developments

4basebio launches enzymatic ssDNA platform

4basebio (AIM: 4BB) has announced the commercial launch of its high-capacity single-stranded DNA (ssDNA) product line to accelerate the development of safer, more precise genetic therapies by enabling targeted gene...

May 11, 2026

Developments

Pentixapharm submits IND for hypertension diagnostic program

Pentixapharm Holding (Frankfurt Prime Standard: PTP) announced the submission of an Investigational New Drug (IND) application to the FDA for its lead CXCR4-targeted diagnostic program in treatment resistant...

May 11, 2026

Developments

JAMA Network Open publishes Red Light’s trial of psilocybin in cocaine use disorder

Red Light Holland (CSE: TRIP; FSE: 4YX; OTCQB: TRUFF) has highlighted the publication of a peer-reviewed randomized clinical trial in the Journal of American Medical Association (JAMA) Network Open evaluating a single...

May 8, 2026

Developments

Vistagen reports last patient visit in trial of fasedienol nasal spray in SAD

Vistagen (NASDAQ: VTGN) has announced that the last patient has completed the last visit in the randomized, double-blind, placebo-controlled portion of PALISADE-4, the Phase 3 clinical trial evaluating fasedienol nasal...

May 8, 2026

Developments

PharmaJet Tropis Needle-free Injection System selected to deliver 1.4 million polio vaccine doses in Nigeria

Closely held PharmaJet announced that its WHO-prequalified Tropis ID Needle-free Injection System will be used to deliver approximately 1.4 million doses of fractional inactivated polio vaccine (fIPV), in partnership...

May 7, 2026

Developments

Entrada reveals positive topline results from study of ENTR-601-44 in DMD

Entrada Therapeutics (NASDAQ: TRDA) has announced positive topline data from Cohort 1 of the double-blind, placebo-controlled, multiple ascending dose portion of the Phase 1/2 ELEVATE-44-201 clinical study of ENTR-601...

May 7, 2026

Category - Developments

Subscribe